Supporting Decision-Making on Fertility Preservation Among Adolescent and Young Adult Women With CancerNovember 13th 2020
ABSTRACT Adolescents and young adults (AYAs) with cancer constitute approximately 70,000 patients diagnosed each year. Survival rates for AYAs with cancer have increased steadily in recent decades due to improvements in therapeutic regimens and early detection. Given the large and growing number of AYA cancer survivors, additional research is needed on the immediate and long-term psychosocial support required for this population including family planning and fertility. Fertility and fertility preservation in female AYAs, in particular, is historically understudied and has psychologically relevant ramifications distinct from male AYAs. Decision science can contribute to this area of oncological care and has implications for clinical encounters and research concerning female AYA patients with cancer. Patient-centered care and shared decision-making that integrates recent research regarding fertility preservation in the context of cancer treatment can improve outcomes for AYA cancer survivors.
Strategies for Overcoming Disparities for Patients With Hematologic Malignancies and for Improving Enrollment on Clinical TrialsJune 16th 2020
A multitude of factors contributes to cancer disparities. Addressing these disparities among racial/ethnic minority populations with blood cancers requires multilevel models of the interactions between relevant factors and the performance of translational research that uses knowledge of cancer biology to develop and test the feasibility of interventions that can impact human endpoints. To be effective, efforts should be made to advance these research findings to applications that can transform clinical practice and health care delivery. We reviewed the literature to define a framework for overcoming disparities for patients with hematologic malignancies and to improve patient enrollment in clinical trials.
A Plethora of Novel Therapies-Which One to Choose?July 15th 2015
While the headliners for the 2015 ASCO Annual Meeting featured mainly immunologic approaches to cancer treatment, with agents such as nivolumab and ipilimumab, the new data in hematologic malignancies highlighted a large number of novel therapies, each of which appears promising.
Costs and Effectiveness of Genomic Testing in the Management of Colorectal CancerMarch 15th 2015
Numerous genomic tests are available for use in colorectal cancer, with a widely variable evidence base for their effectiveness and cost-effectiveness. In this review, we highlight many of these tests, with a focus on their proposed role, the evidence base to support that role, and the associated costs and risks.
Routine Use of Maintenance Therapy in Follicular Lymphoma: Examine the Rationale for Maintenance Use Before Uniformly Adopting a StrategySeptember 15th 2014
While definitions of follicular lymphoma maintenance therapy in clinical trials and clinical practice have been somewhat variable, ideally maintenance therapy would be limited to patients in complete remission or with minimal residual disease following initial therapy
Novel Therapies in Mantle Cell Lymphoma: A Pathway to Chemotherapy-Free StrategiesOctober 15th 2013
This review will cover innovative therapeutic approaches in relapsed or refractory MCL, many of which have the potential to alter treatment paradigms toward the development of strategies that do not involve conventional chemotherapy agents.
Peripheral T-Cell Lymphoma: What’s the Role for Transplant?September 15th 2013
The number of recently approved agents and those under investigation is promising. However, there are currently no recommendations regarding the optimal timing for use of these agents, a reflection of the lack of data in this area and the need for prospective studies.
ACR Appropriateness Criteria® Localized Nodal Indolent LymphomaAugust 15th 2013
The present guidelines review epidemiology, pathology, presentation, workup, staging, prognostic factors, and treatment options for patients with localized nodal indolent lymphoma, with an emphasis on radiation guidelines, including radiation dose, field design, and radiation techniques.
Improving Our Use and Understanding of Antibodies in B-cell LymphomasFebruary 11th 2010
In this review, Ujjani and Cheson present a useful overview of the array of existing and developing roles for monoclonal antibodies in the management of B-cell non-Hodgkin lymphomas (NHLs). These roles may be characterized as single-agent antibody therapy, use in combination with chemotherapy and/or other antibodies, and use following an initial regimen (consolidation/maintenance). Rituximab (Rituxan), the first monoclonal antibody approved for B-cell NHL, clearly has had greatest application in each of these arenas, but it has now been joined by alemtuzumab (Campath) and ofatumumab (Arzerra) as approved single-agent therapies. Also highlighted are a number of other antibodies aimed at B-cell targets: veltuzumab, GA101, AME-133 (CD20), epratuzumab (CD22), lumiliximab (CD23), galiximab (CD80), dacetuzumab (CD40), mapatumumab, lexatumumab (TRAIL), and approaches to improve antibody therapy such as conjugation with radioisotopes or toxins.